Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Darwin Biosciences has developed a saliva-based diagnostic platform capable of detecting early immune responses to infection. Their technology was proven comparable to other COVID‑19 tests and used thousands of times. They have completed a Phase 1 clinical trial using their platform in an influenza challenge study to identify saliva biomarkers for early infection detection, agnostic to the specific pathogen. The company is pursuing additional applications from sepsis to Ebola and is actively seeking strategic partnerships.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Darwin Biosciences.